Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005967 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00005967: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00005967 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005967, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Randomized phase I trial to study the effectiveness of tipifarnib in treating patients who have advanced hematologic cancer. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
Interventions
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2000-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005967
The ClinicalTrials.gov registry entry for NCT00005967 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tipifarnib is the first listed.
NCT00005967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005967 about?
NCT00005967 is a clinical study titled "Tipifarnib in Treating Patients With Advanced Hematologic Cancer". Randomized phase I trial to study the effectiveness of tipifarnib in treating patients who have advanced hematologic cancer. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
What is the current status of trial NCT00005967?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2000-08.
What interventions are being tested in trial NCT00005967?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00005967?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.